选择语言

Human c-MET (Luc) HEK293 Reporter Cell

用户评价
货号-规格
价格
Qty.
CHEK-ATF144-2Vials (1Vial X 2)
询价
合计0件 产品金额¥ 0

产品详情

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • 描述(Description)

    The Human c-MET (Luc) HEK293 Reporter Cell was engineered to express signaling response element driving luciferase expressing systems and human c-MET (Gene ID: 4233). When stimulated with human HGF protein, the HGF/c-MET interaction drives RE-mediated luminescence. Neutralization of biological effect of human HGF protein by corresponding antibody results in a decrease in luminescence.

  • 应用说明(Application)

    • Screen for neutralizing antibodies blocking the stimulation of human HGF protein.

    HGF R Assay Principles

  • 生长特性(Growth Properties)

    Adherent

  • 筛选标记(Selection Marker)

    Puromycin (2 μg/mL)

  • 培养基(Complete Growth Medium)

    DMEM + 10% FBS

  • 冻存液(Freeze Medium)

    Serum-free cell cryopreservation medium

  • 装量(Quantity)

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • 存储(Storage)

    Frozen in liquid nitrogen.

  • 支原体检测(Mycoplasma Testing)

    Negative

  • 无菌检测(Sterility Testing)

    Negative

  • 使用说明(Instructions for Use)

    See data sheet for detailed culturing and assay protocol.

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

数据展示

  • Receptor Assay

     HGF R FACS

    Expression analysis of human c-MET on Human c-MET (Luc) HEK293 Reporter Cell by FACS.
    Cell surface staining was performed on Human c-MET (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human c-MET antibody.

    Protocol
  • Application

     HGF R APPLICATION

    Inhibition of human HGF protein-induced reporter activity by anti-human c-MET neutralizing antibody.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of human HGF protein with a final concentration of 0.05 μg/mL. The EC50 of anti-human c-MET neutralizing antibody (Amivantamab) is approximately 0.06561 μg/mL.

    Protocol
  • Signaling Bioassay

     HGF R SIGNALING

    Response to human HGF protein (RLU).
    This reporter cell was incubated with serial dilutions of human HGF protein. The EC50 was approximately 0.03652 μg/mL.

    Protocol
  •  HGF R SIGNALING

    Response to human HGF protein (FOLD).
    This reporter cell was incubated with serial dilutions of human HGF protein. The max induction fold was approximately 38.12.

    Protocol
*如有相关细胞池需求请联系我们

用户评价
发表评论

重要声明

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

前沿进展

 
药物研发进展
  • 英文全称:

    Hepatocyte growth factor receptor

  • 中文全称:

    肝细胞生长因子受体

  • 种类:

  • 上市药物数量:

    11 详情

  • 临床药物数量:

    65 详情

  • 最高研发阶段:

    临床二期

联系我们
项目合作
查看更多项目
  • 产品基础信息
  • 产品详情
  • 数据展示
  • 用户评价
  • 重要声明